LIXTE Adds Northwestern University’s Lurie Cancer Center as Second Site in Ongoing ...
Lurie Cancer Center Completes Dosing of First Patient with LIXTE’s LB-100 in Combination with GSK’s Immunotherapy Dostarlimab --PASADENA, ...
precisionmedicineonline18 小时
Allarity Therapeutics Advances New Protocol for Stenoparib Phase II Ovarian Cancer Trial
The firm will test additional doses and use its proprietary drug response predictor to gather data that can inform a registrational study.